Study title: Referenced in Rifater Registration Dossier - Clinical Documentation - Update April 1998 : The use of fixed-dose combinations in antituberculosis chemotherapy. Rationale for their application in daily, intermittant and pediatric regimens. - Acoccella G. - 1990 (Bulletin of the Int. Union Against Tuberculosis and Lung Disease, 65, 2-3: 77-83)
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Bacterial Infections and Mycoses | |||||
| Brands: Please see report | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: RIFAMPICIN/ISONIAZID/PYRAZINAMIDE | |||||
| ATC code: | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | - | |